Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Alabama for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Alabama only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Alabama (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Benjamin Miriovsky (NPI 1427234277)

Field	Value
Entity Type	Individual
Organization	Benjamin Miriovsky
Address	1 Hospital Dr Sw Ste 400
City	Huntsville
State	AL
ZIP	35801
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	January 10, 2008

Payer Source	Total Paid
Medicare	$1.3M
Medicaid	$0

Key Findings

This provider is a Hematology & Oncology Physician in Huntsville, AL with an NPI enumerated on 2008-01-10 (~18 years ago), indicating long-standing Medicare participation and clinical tenure in oncology/hematology care. The longevity of enrollment suggests stable practice presence and experience treating Medicare beneficiaries over many years.

Medicare dominates this provider's payer mix: lifetime Medicare revenue is $1.3M while there is no Medicaid billing on file, making the practice effectively single-payer (Medicare-focused) in the available dataset. Analysts should treat Medicaid-related service demand and state-level competitive dynamics as not observable for this provider.

Revenue concentration is high in a few drug administration codes: the precomputed top 3 Medicare codes by revenue account for 52.4% of total Medicare revenue. The single largest code is J9271 (pembrolizumab) contributing $268.8K (22.9% of Medicare revenue), followed by Q5127 (pegfilgrastim-fpgk biosimilar) at $198K (16.8%) and J1568 (IV immune globulin) at $149.6K (12.7%); this mix signals dependence on high-cost oncology and supportive-care biologics.

The code mix and descriptions reflect an oncology-focused infusion practice model: high-volume biologic/antineoplastic drug injections (J9271, Q5127), intravenous immune globulin (J1568), denosumab (J0897), and multiple chemotherapy administration codes (96413, 96365, 96417) point to routine outpatient infusion and supportive oncology services rather than primarily procedural or surgical care. Frequent use of E/M office visit codes (99214, 99213, 99215) alongside infusion codes indicates integrated office-based oncology follow-up and management.

Competitive standing by code is mixed: the provider ranks in the top percentiles nationally for some routine oncology-support codes (for example, 99214 at the 97th percentile is notably above typical national volume, and 96375 at the 97th percentile is also labeled notably above typical national volume), suggesting strong throughput for office E/M and IV push follow-up infusions. In contrast, J9271 (pembrolizumab) ranks at the 13th percentile nationally (typical, unremarkable volume), indicating the provider is not a high-volume national outlier for that specific checkpoint inhibitor relative to peers.

Several supportive and infusion-related codes show unusually high relative ranks within their respective national cohorts: 96375 (IV push sequential infusion) ranks in the 97th percentile and 80053/85025/36415 laboratory and phlebotomy codes rank at or above the high 90s percentiles, which together imply substantial on-site infusion throughput with associated lab monitoring and blood draws. These high ranks suggest strong operational capacity for infusion visits and ancillary testing.

Some high-claim-volume medication administration codes have modest per-claim payments but still contribute materially to revenue due to claim counts — for example, J0881 (darbepoetin alfa) shows 10.1K claims with $2 avg paid/claim for $20.2K revenue, and J0185 (aprepitant) shows 8.3K claims with $1 avg paid/claim for $8.3K revenue. This pattern indicates the practice delivers many low-price supportive agents alongside higher-cost biologics, consistent with routine outpatient oncology care.

Geographic and national competitive signals diverge across codes: certain biologics and infusions place the provider in relatively high national percentiles for volume among smaller cohorts (e.g., Q5127 at the 83th percentile, J1750 iron dextran at the 86th percentile), while large national cohorts for common E/M and lab codes place the provider at very high absolute rank counts but more moderate percentiles; overall this portrays a modest-to-strong regional player with pockets of higher specialization rather than a dominant national center for oncology drugs.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

81 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	6,400	$40	$268.8K
Q5127	Injection, pegfilgrastim-fpgk (stimufend), biosimilar, 0.5 mg	720	$280	$198K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	4,400	$30	$149.6K
J0897	Injection, denosumab, 1 mg	7,380	$20	$132.8K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	960	$90	$85.4K
J1437	Injection, ferric derisomaltose, 10 mg	4,100	$20	$69.7K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	450	$90	$39.2K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	110	$320	$33.3K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	10,110	$1	$20.2K
80053	The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel.	1,990	$10	$19.9K

Showing 1–10 of 81

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 81 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Alabama Distribution

Benjamin Miriovsky — 5 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Alabama

Full comparison — all codes billed, vs. state median

81 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	32	30	19,900	$40	$827.2K
J1568	24	30	5,180	$30	$316.2K
Q5127	5	20	590	$270	$165.7K
J0897	43	200	3,120	$20	$97.7K
J1437	12	40	3,000	$20	$59.1K
J1454	8	20	90	$340	$33.7K
J0881	12	30	7,720	$1	$24.1K
J9217	43	50	130	$130	$22.4K
96413	27	150	150	$90	$20.2K
99214	194	7,330	120	$80	$16.8K

Showing 1–10 of 81

Related Providers

Other providers that share a Tax Identification Number (TIN) with Benjamin Miriovsky, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Bend Memorial Clinic PC	OR	Family Medicine Physician	$0	$11.7M
John Waples	AL	Medical Oncology Physician	$9.6M	$0
Marshall Schreeder	AL	Medical Oncology Physician	$3.5M	$0
Heather Brody	AL	Hematology & Oncology Physician	$3.1M	$0
Anthony Kahr	OR	Rheumatology Physician	$2.8M	$0
Jorge Diaz	AL	Hematology & Oncology Physician	$2.6M	$0
Naveen Lobo	AL	Medical Oncology Physician	$2.4M	$0
Ali Hachem	AL	Hematology & Oncology Physician	$2.3M	$0
Daniel Schreeder	AL	Hematology & Oncology Physician	$2.3M	$0
Laith Kadasi	OR	Ophthalmology Physician	$2.2M	$0

Nearby Providers

Other providers in the same ZIP code as Benjamin Miriovsky, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Tennessee Valley Neonatology, Inc	AL	Neonatal-Perinatal Medicine Physician	$0	$22.2M
The Health Care Authority Of The City Of Huntsville	AL	General Acute Care Hospital	$0	$17.8M
Happi Health	AL	Federally Qualified Health Center (FQHC)	$0	$17.6M
Emergency Physicians Group	AL	Emergency Medicine Physician	$0	$13.5M
Healthgroup Of Alabama	AL	Contractor	$0	$13.4M
The Valley Foundation	AL	Multi-Specialty Clinic/Center	$0	$11.3M
David White	AL	Neurology Physician	$7M	$0
The Children's Hospital Of Alabama	AL	Pediatric Pulmonology Physician	$0	$5.6M
Huntsville Pediatric Associates, LLC	AL	Pediatrics Physician	$0	$4.8M
Dental Associates Of Huntsville, LLC	AL	General Practice Dentistry	$0	$4.7M

Benjamin Miriovsky — Billing Profile & Reimbursement Data

Sign up for Benjamin Miriovsky — Billing Profile & Reimbursement Data policy alerts

Benjamin Miriovsky — Billing Profile & Reimbursement Data

Sign up for Benjamin Miriovsky — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References